Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201 Meeting Abstract
| Authors: | Andreadis, C.; Bobek, O.; Hsi, E. D.; Fenske, T. S.; Geyer, S. M.; Stiff, P. J.; Hill, B. T.; Horwitz, M.; Khimani, F.; Little, R. F.; Dinner, S. N.; Friedberg, J. W.; Kahl, B. S.; Perales, M. A.; Devine, S. M.; Leonard, J. P.; Bartlett, N. L. |
| Abstract Title: | Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201 |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 437 |
| Language: | English |
| ACCESSION: | WOS:001159306701194 |
| DOI: | 10.1182/blood-2023-173742 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
